Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Arcellx, Inc. Market Cap
The Arcellx, Inc. (ACLX) share price is expected to increase by 39.1% over the next year. This is based on calculating the average 12-month share price estimate provided by 19 stock analysts who have covered ACLX. Price targets range from $95 at the low end to $134 at the high end. The current analyst consensus for ACLX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 19 Wall Street analysts have assignedACLX 19 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Arcellx, Inc. to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ACLX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ACLX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Asthika Goonewardene Truist Securities | Buy | $136 | Maintains | Nov 12, 2024 |
| Biren Amin Piper Sandler | Overweight | $115 | Maintains | Nov 8, 2024 |
| Gil Blum Needham | Buy | $105 | Maintains | Nov 8, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $115 | Maintains | Nov 8, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $95 | Maintains | Nov 6, 2024 |
| Judah Frommer Morgan Stanley | Overweight | $106 | Maintains | Nov 6, 2024 |
| Jack Allen Baird | Outperform | $106 | Maintains | Nov 6, 2024 |
| Gil Blum Needham | Buy | $96 | Reiterates | Nov 6, 2024 |
| Jason Gerberry B of A Securities | Buy | $100 | Maintains | Nov 6, 2024 |
| Gil Blum Needham | Buy | $96 | Reiterates | Oct 31, 2024 |
| Gil Blum Needham | Buy | $96 | Maintains | Oct 22, 2024 |
| Benjamin Burnett Stifel | Buy | $122 | Maintains | Oct 18, 2024 |
| John Newman Canaccord Genuity | Buy | $115 | Maintains | Oct 17, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | Reiterates | Sep 9, 2024 | |
| Rick Bienkowski Cantor Fitzgerald | Overweight | Initiates | Sep 3, 2024 | |
| Gil Blum Needham | Buy | $81 | Reiterates | Aug 9, 2024 |
| John Newman Canaccord Genuity | Buy | $85 | Maintains | Jul 22, 2024 |
| Asthika Goonewardene Truist Securities | Buy | $87 | Maintains | Jun 18, 2024 |
| Biren Amin Piper Sandler | Overweight | $70 | Initiates | May 31, 2024 |
| Benjamin Burnett Stifel | Buy | $83 | Maintains | May 15, 2024 |
When did it IPO
N/A
Staff Count
130
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Rami Elghandour
Market Cap
$4.82B
In 2023, ACLX generated $110.3M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ACLX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 09 Dec 2024
Sentiment - POSITIVE
Source - Investors Business Daily
Summary - Arcellx stock declined after positive results for a competitor to Legend Biotech's multiple myeloma treatment, Carvykti, were announced.
Why It Matters - Arcellx's stock decline amid rival success signals competitive pressures and potential market share loss, affecting investor sentiment and future valuations in the biotech sector.
Mon, 09 Dec 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - Arcellx, Inc. (ACLX) announced new data from its Phase 2 iMMagine-1 study on anitocabtagene autoleucel for relapsed or refractory multiple myeloma patients.
Why It Matters - New data from Arcellx's pivotal study could impact its stock price and market perception, indicating potential advancements in treatment for a significant patient population.
Sun, 08 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Arcellx, Inc. (NASDAQ: ACLX) announced positive results from its Phase 2 iMMagine-1 study on anitocabtagene autoleucel for relapsed or refractory multiple myeloma, to be presented at the ASH conference.
Why It Matters - Positive Phase 2 data for Arcellx's anito-cel in treating RRMM could boost investor confidence, potentially leading to increased stock value and market interest in the company's future.
Wed, 13 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Arcellx, Inc. (ACLX) is being evaluated for its potential as a top stock pick for momentum investors. Further analysis is needed to determine its viability.
Why It Matters - The focus on Arcellx, Inc. (ACLX) as a potential momentum stock indicates investor interest and could signal volatility and trading opportunities, impacting market sentiment and stock performance.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Arcellx, Inc. (NASDAQ: ACLX) reported Q3 2024 financial results, highlighting advancements in their cancer immunotherapy, anito-cel, which shows promise as a best-in-class treatment.
Why It Matters - Arcellx's positive clinical data and Q3 financial results signal strong potential for its therapies, which could drive stock performance and investor interest in the biotech sector.
Thu, 07 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Arcellx, Inc. (ACLX) reported a quarterly loss of $0.48 per share, better than the expected loss of $0.54, and improved from a loss of $0.81 per share a year earlier.
Why It Matters - Arcellx's smaller-than-expected loss indicates improved financial performance, potentially boosting investor confidence and interest in the stock.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
